Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 4 July

Sophia Mavridis
July 4, 2022

Weekly Wrap 1 July

Sophia Mavridis
July 1, 2022

Morning Bell 30 June

Paulina Peters
June 30, 2022

Morning Bell 29 June

Sophia Mavridis
June 29, 2022

Morning Bell 28 June

Paulina Peters
June 28, 2022

Morning Bell 27 June

Sophia Mavridis
June 27, 2022

Weekly Wrap 24 June

Sophia Mavridis
June 24, 2022

Morning Bell 23 June

Paulina Peters
June 23, 2022

Morning Bell 22 June

Sophia Mavridis
June 22, 2022

Morning Bell 21 June

Paulina Peters
June 21, 2022